Sun Pharmaceutical Industries Limited appears to be a financially stable company with a strong gross margin of 79.56% and EBITDA margin of 28.69%. However, the company's profitability is a concern, with a low ROE of 15.71% and declining earnings growth of -18.8%. The valuation seems stretched, with a high trailing P/E of 36.48 and forward P/E of 50.85. The company's debt-to-equity ratio of 3.26 is a weakness, but its dividend yield of 0.66% is a positive. Overall, the company's financial health is mixed, with strengths in its margins and dividend yield, but weaknesses in its profitability and debt position.